


## Borsa di Studio «Andrea Mezzetti» 2019

**Role of PCSK9 in Alzheimer's Disease: focus on  
inflammation and lipid metabolism**



**Cinzia Marchi**

Dipartimento di Scienze degli Alimenti e del Farmaco  
Università di Parma

# GENES INVOLVED IN CHOLESTEROL AND LIPID METABOLISM AMONG THE ALZHEIMER'S DISEASE SUSCETIBLE LOCI





# Cholesterol in the brain




- Brain contains approximately 30% of total body cholesterol;
- Cholesterol in central nervous system plays crucial roles: important component of myelin, neuronal development, synaptogenesis, maintenance and repair of damaged membranes;
- Brain cholesterol is mainly synthesized *in situ* and provided by de novo synthesis. Peripheral cholesterol can not cross the blood-brain barrier;
- Neurons progressively lose their capacity to synthesize cholesterol during adulthood.

# Brain cholesterol transport from astrocytes to neurons





# PCSK9 and CEREBRAL LIPID METABOLISM




PCSK9 induces the degradation of apoE neuronal receptors implicated in neuronal cholesterol internalization

# PCSK9 and MACROPHAGE LIPID METABOLISM




PCSK9 plays a direct role on Abca1-mediated cholesterol efflux through a downregulation of Abca1 gene and Abca1 protein expression




# PCSK9 and MACROPHAGE INFLAMMATION

1.




1. PCSK9 increases the expression of CD36 in macrophages, microglial-like cells;
2. PCSK9 drives an inflammatory response on macrophages by inducing the pro-inflammatory cytokines

2.



# PCSK9 CSF levels are increased in AD patients



## AIM of THE PROJECT


To investigate the molecular mechanisms by which PCSK9 may exert a pathogenetic role and a deleterious effect on brain cells by negatively modulating **cholesterol homeostasis** or **neuroinflammation** through *in vitro* studies

## HYPOTHESES:

1. PCSK9 degrades apoE neuronal receptors relevant for the cholesterol internalization and therefore neuronal functions;
2. PCSK9 reduces ABCA1 expression in astrocytes, preventing apoE lipidation and consequent generation of HDL-like particles;
3. PCSK9 modulates CD36 expression in microglia, resulting in amplified A $\beta$ -dependent neuroinflammation.


# Cellular models:

In vitro studies



ASTROCYTES


U373  
±  
Human recombinant  
PCSK9



NEURONS

- SH-SY5Y ±  
Human recombinant  
PCSK9
- SH-SY5Y control and  
overexpressing PCSK9

CHOLESTEROL METABOLISM




MICROGLIA

HMC3 ± A $\beta$   
±  
Human recombinant  
PCSK9


NEUROINFLAMMATION

## IMPACT OF PCSK9 ON CHOLESTEROL METABOLISM:




ASTROCYTES:


- Cholesterol efflux
- Expression of receptors involved in brain cholesterol efflux: i.e. ABCA1 and ABCG1
- Endogenous cholesterol synthesis
- Membrane cholesterol distribution



## IMPACT OF PCSK9 ON CHOLESTEROL METABOLISM:




NEURONS:



- Cholesterol uptake
- Expression of receptors involved in cholesterol uptake: i.e. ApoER2, LDLr, LRP-1
- Endogenous cholesterol synthesis
- Membrane cholesterol distribution
- Consequences of PCSK9-induced alteration of lipid metabolism on:
  - 1) apoptosis (caspase 3 levels)
  - 2) A $\beta$  production

# IMPACT OF PCSK9 ON NEUROINFLAMMATION:

*In vitro studies*



MICROGLIA:

- Inflammatory response to A $\beta$ : levels of IL-6, IL-1 $\beta$  and TNF- $\alpha$
- Expression of CD36

## EXPECTED OUTCOMES:

Provide new perspectives for understanding the connection between PCSK9, brain cholesterol metabolism and neuroinflammation

Fill the existing knowledge gap on PCSK9 potential involvement in Alzheimer's Disease

Identify PCSK9 as a novel player and potential therapeutic target for future pharmacological strategies



## ACKNOWLEDGMENTS:


**Department of Food and Drug  
University of Parma**

Franco Bernini

Francesca Zimetti

Maria Pia Adorni

Bianca Papotti



**Department of Pharmaceutical and  
Pharmacological Sciences**

**University of Padova**

Nicola Ferri

Maria Giovanna Lupo

Noemi Biancorosso